ComplianceOnline

Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR

  • Date: May 04, 2010
  • Source: www.fda.gov
Webinar All Access Pass Subscription Abstract:

The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

Bookmark and Share
Best Sellers
You Recently Viewed
    Loading